Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/228

Result Summary for 101468/228

Result Summary

Protocol ID:	101468/228
Clinical Study ID:	101468/228
Official Title:	A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects.
Phase:	phase 3
Study Indications or Diseases:	Parkinson Disease
Generic Name:	ropinirole
Trade/Product Name:	Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	R Watts, K Sethi, R Pahwa, B Adams, N Earl. Ropinirole 24-hour prolonged release delays the onset of dyskinesia compared with carbidopa/levodopa in patients with Parkinson’s disease treated with levodopa. Movement Disorders. 2007;22 (Suppl.16):S94/307. R Watts, K Sethi, R Pahwa, B Adams, N Earl. Ropinirole 24-hour prolonged release delays the onset of dyskinesia Compared with carbidopa/levodopa in patients with Parkinson’s disease treated with levodopa. Eur J Neurol. 2007;14 (Issue s1):1-355 . Ray Watts, Rajesh Pahwa, Kelly Lyons, Kapil Sethi, Matthew Stern, Robert Hauser, Warren Olanow, Alex Gray, Bryan Adams, Nancy Earl. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.. [Mov Disord]. 2010;25(7):858-66.